PMC:7373848 / 14385-14949
Annnotations
LitCovid-PD-FMA-UBERON
{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T234","span":{"begin":236,"end":253},"obj":"Body_part"},{"id":"T235","span":{"begin":248,"end":253},"obj":"Body_part"},{"id":"T236","span":{"begin":307,"end":316},"obj":"Body_part"},{"id":"T237","span":{"begin":326,"end":334},"obj":"Body_part"},{"id":"T238","span":{"begin":355,"end":372},"obj":"Body_part"},{"id":"T239","span":{"begin":432,"end":436},"obj":"Body_part"}],"attributes":[{"id":"A234","pred":"fma_id","subj":"T234","obj":"http://purl.org/sig/ont/fma/fma66772"},{"id":"A235","pred":"fma_id","subj":"T235","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A236","pred":"fma_id","subj":"T236","obj":"http://purl.org/sig/ont/fma/fma63174"},{"id":"A237","pred":"fma_id","subj":"T237","obj":"http://purl.org/sig/ont/fma/fma63174"},{"id":"A238","pred":"fma_id","subj":"T238","obj":"http://purl.org/sig/ont/fma/fma63872"},{"id":"A239","pred":"fma_id","subj":"T239","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Schematic representation of the Ang2 effect on the vascular bed in normal conditions, inflammation, and cancer. Under normal physiological conditions, Ang2 levels are low, but are upregulated during inflammation or cancer. Ang2 acts on endothelial cells, increasing endothelial permeability and also on the pericytes, causing pericyte detachment from the basement membrane, further inducing vascular leakiness, immune or/and cancer cell trans-endothelial migration, and deterioration of the condition. Ang2 has been proposed as a marker for inflammatory conditions"}
LitCovid-PubTator
{"project":"LitCovid-PubTator","denotations":[{"id":"202","span":{"begin":32,"end":36},"obj":"Gene"},{"id":"203","span":{"begin":151,"end":155},"obj":"Gene"},{"id":"204","span":{"begin":223,"end":227},"obj":"Gene"},{"id":"205","span":{"begin":502,"end":506},"obj":"Gene"},{"id":"206","span":{"begin":86,"end":98},"obj":"Disease"},{"id":"207","span":{"begin":104,"end":110},"obj":"Disease"},{"id":"208","span":{"begin":199,"end":211},"obj":"Disease"},{"id":"209","span":{"begin":215,"end":221},"obj":"Disease"},{"id":"210","span":{"begin":391,"end":409},"obj":"Disease"},{"id":"211","span":{"begin":425,"end":431},"obj":"Disease"}],"attributes":[{"id":"A202","pred":"tao:has_database_id","subj":"202","obj":"Gene:285"},{"id":"A203","pred":"tao:has_database_id","subj":"203","obj":"Gene:285"},{"id":"A204","pred":"tao:has_database_id","subj":"204","obj":"Gene:285"},{"id":"A205","pred":"tao:has_database_id","subj":"205","obj":"Gene:285"},{"id":"A206","pred":"tao:has_database_id","subj":"206","obj":"MESH:D007249"},{"id":"A207","pred":"tao:has_database_id","subj":"207","obj":"MESH:D009369"},{"id":"A208","pred":"tao:has_database_id","subj":"208","obj":"MESH:D007249"},{"id":"A209","pred":"tao:has_database_id","subj":"209","obj":"MESH:D009369"},{"id":"A210","pred":"tao:has_database_id","subj":"210","obj":"MESH:C535298"},{"id":"A211","pred":"tao:has_database_id","subj":"211","obj":"MESH:D009369"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Schematic representation of the Ang2 effect on the vascular bed in normal conditions, inflammation, and cancer. Under normal physiological conditions, Ang2 levels are low, but are upregulated during inflammation or cancer. Ang2 acts on endothelial cells, increasing endothelial permeability and also on the pericytes, causing pericyte detachment from the basement membrane, further inducing vascular leakiness, immune or/and cancer cell trans-endothelial migration, and deterioration of the condition. Ang2 has been proposed as a marker for inflammatory conditions"}
LitCovid-PD-MONDO
{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T47","span":{"begin":86,"end":98},"obj":"Disease"},{"id":"T48","span":{"begin":104,"end":110},"obj":"Disease"},{"id":"T49","span":{"begin":199,"end":211},"obj":"Disease"},{"id":"T50","span":{"begin":215,"end":221},"obj":"Disease"},{"id":"T51","span":{"begin":425,"end":431},"obj":"Disease"}],"attributes":[{"id":"A47","pred":"mondo_id","subj":"T47","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"},{"id":"A48","pred":"mondo_id","subj":"T48","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A49","pred":"mondo_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"},{"id":"A50","pred":"mondo_id","subj":"T50","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A51","pred":"mondo_id","subj":"T51","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"}],"text":"Schematic representation of the Ang2 effect on the vascular bed in normal conditions, inflammation, and cancer. Under normal physiological conditions, Ang2 levels are low, but are upregulated during inflammation or cancer. Ang2 acts on endothelial cells, increasing endothelial permeability and also on the pericytes, causing pericyte detachment from the basement membrane, further inducing vascular leakiness, immune or/and cancer cell trans-endothelial migration, and deterioration of the condition. Ang2 has been proposed as a marker for inflammatory conditions"}
LitCovid-PD-CLO
{"project":"LitCovid-PD-CLO","denotations":[{"id":"T250","span":{"begin":236,"end":253},"obj":"http://purl.obolibrary.org/obo/CL_0000115"},{"id":"T251","span":{"begin":355,"end":372},"obj":"http://purl.obolibrary.org/obo/UBERON_0005769"},{"id":"T252","span":{"begin":432,"end":436},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T253","span":{"begin":507,"end":510},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T254","span":{"begin":528,"end":529},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Schematic representation of the Ang2 effect on the vascular bed in normal conditions, inflammation, and cancer. Under normal physiological conditions, Ang2 levels are low, but are upregulated during inflammation or cancer. Ang2 acts on endothelial cells, increasing endothelial permeability and also on the pericytes, causing pericyte detachment from the basement membrane, further inducing vascular leakiness, immune or/and cancer cell trans-endothelial migration, and deterioration of the condition. Ang2 has been proposed as a marker for inflammatory conditions"}
LitCovid-PD-HP
{"project":"LitCovid-PD-HP","denotations":[{"id":"T16","span":{"begin":104,"end":110},"obj":"Phenotype"},{"id":"T17","span":{"begin":215,"end":221},"obj":"Phenotype"},{"id":"T18","span":{"begin":425,"end":431},"obj":"Phenotype"}],"attributes":[{"id":"A16","pred":"hp_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/HP_0002664"},{"id":"A17","pred":"hp_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/HP_0002664"},{"id":"A18","pred":"hp_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"Schematic representation of the Ang2 effect on the vascular bed in normal conditions, inflammation, and cancer. Under normal physiological conditions, Ang2 levels are low, but are upregulated during inflammation or cancer. Ang2 acts on endothelial cells, increasing endothelial permeability and also on the pericytes, causing pericyte detachment from the basement membrane, further inducing vascular leakiness, immune or/and cancer cell trans-endothelial migration, and deterioration of the condition. Ang2 has been proposed as a marker for inflammatory conditions"}
LitCovid-PD-GO-BP
{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T57","span":{"begin":86,"end":98},"obj":"http://purl.obolibrary.org/obo/GO_0006954"},{"id":"T58","span":{"begin":199,"end":211},"obj":"http://purl.obolibrary.org/obo/GO_0006954"}],"text":"Schematic representation of the Ang2 effect on the vascular bed in normal conditions, inflammation, and cancer. Under normal physiological conditions, Ang2 levels are low, but are upregulated during inflammation or cancer. Ang2 acts on endothelial cells, increasing endothelial permeability and also on the pericytes, causing pericyte detachment from the basement membrane, further inducing vascular leakiness, immune or/and cancer cell trans-endothelial migration, and deterioration of the condition. Ang2 has been proposed as a marker for inflammatory conditions"}
LitCovid-sentences
{"project":"LitCovid-sentences","denotations":[{"id":"T96","span":{"begin":112,"end":222},"obj":"Sentence"},{"id":"T97","span":{"begin":223,"end":501},"obj":"Sentence"},{"id":"T98","span":{"begin":502,"end":564},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Schematic representation of the Ang2 effect on the vascular bed in normal conditions, inflammation, and cancer. Under normal physiological conditions, Ang2 levels are low, but are upregulated during inflammation or cancer. Ang2 acts on endothelial cells, increasing endothelial permeability and also on the pericytes, causing pericyte detachment from the basement membrane, further inducing vascular leakiness, immune or/and cancer cell trans-endothelial migration, and deterioration of the condition. Ang2 has been proposed as a marker for inflammatory conditions"}
LitCovid-PMC-OGER-BB
{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T494","span":{"begin":32,"end":36},"obj":"PR:000004024"},{"id":"T495","span":{"begin":51,"end":63},"obj":"UBERON:0002049"},{"id":"T496","span":{"begin":151,"end":155},"obj":"PR:000004024"},{"id":"T497","span":{"begin":223,"end":227},"obj":"PR:000004024"},{"id":"T498","span":{"begin":236,"end":247},"obj":"UBERON:0001986;CL:0000115"},{"id":"T499","span":{"begin":248,"end":253},"obj":"CL:0000115"},{"id":"T500","span":{"begin":266,"end":277},"obj":"UBERON:0001986"},{"id":"T501","span":{"begin":307,"end":316},"obj":"CL:0000669"},{"id":"T502","span":{"begin":326,"end":334},"obj":"CL:0000669"},{"id":"T503","span":{"begin":411,"end":417},"obj":"UBERON:0002405"},{"id":"T504","span":{"begin":443,"end":454},"obj":"UBERON:0001986;GO:0001755"},{"id":"T505","span":{"begin":455,"end":464},"obj":"GO:0001764"},{"id":"T506","span":{"begin":502,"end":506},"obj":"PR:000004024"}],"text":"Schematic representation of the Ang2 effect on the vascular bed in normal conditions, inflammation, and cancer. Under normal physiological conditions, Ang2 levels are low, but are upregulated during inflammation or cancer. Ang2 acts on endothelial cells, increasing endothelial permeability and also on the pericytes, causing pericyte detachment from the basement membrane, further inducing vascular leakiness, immune or/and cancer cell trans-endothelial migration, and deterioration of the condition. Ang2 has been proposed as a marker for inflammatory conditions"}